Abstract A088: SLC39A6-targeted combination therapy to reverse CAF-induced resistance in HER2+ breast cancer using a microfluidic platform
HER2+ breast cancer accounts for 15–20% of invasive breast cancers, and although eight FDA-approved agents, including monoclonal antibodies, tyrosine-kinase inhibitors, and antibody-drug conjugates, have substantially improved patient survival, resistance in the advanced disease setting remains a significant unmet cl...